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Currently, there are many studies that corroborate the relationship between the 
microbiota and the gut – brain axis. This relationship is due through various mechanisms 
including the production of some metabolites by the microbiota, such as short – chain 
fatty acids. The microbiota – gut – brain axis consists in the bidirectional communication 
between the microbiota, the gut and the brain where changes in the microbiota can lead 
to changes in the gut and brain, and vice versa. The aim of the research is to study the 
impact of short – chain fatty acids on the axis. A bibliographic research was performed 
through some search engines. Studies show that short – chain fatty acids have different 
effects by increasing or decreasing the quantity of certain molecules such as GLP-1, 
peptide YY, insulin, glucagon, ghrelin, leptin and serotonin while they also have an 
impact on the nervous system. Also is needed to emphasize its role in certain 
neurological diseases such as Parkinson, autism spectrum disorder and multiple 
sclerosis. However, the current evidence still needs to be strengthened by further 
studies that will allow to define the mechanisms by which this relationship takes place 
and confirm the impact of this type of metabolites on the organism. At the same time, 
this will allow to develop new treatments for people with certain neurological diseases. 




A dia d’avui són molts els estudis que corroboren la relació entre la microbiota i l’eix 
intestí – cervell. Aquesta relació es dona mitjançant diversos mecanismes entre els quals 
hi ha la producció de certs metabòlits per part de la microbiota, com són els àcids grassos 
de cadena curta. L’eix microbiota – intestí – cervell consisteix en una comunicació 
bidireccional entre la microbiota, l’intestí i el cervell on modificacions a nivell de la 
microbiota poden donar lloc a canvis a nivell intestinal i cerebral i viceversa. L’objectiu 
de la recerca consisteix en l’estudi de l’impacte dels àcids grassos de cadena curta sobre 
l’eix. Per fer-ho s’ha realitzat una recerca bibliogràfica mitjançant alguns motors de 
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cerca. Els estudis mostren que els àcids grassos de cadena curta tenen accions a 
diferents nivells incrementant o disminuint la quantitat de certes molècules com el GLP-
1, pèptid YY, insulina, glucagó, grelina, leptina i serotonina a la vegada que també tenen 
un impacte sobre el sistema nerviós. Cal destacar també, el seu paper en certes malalties 
neurològiques com el Parkinson, trastorn de l’espectre autista i l’esclerosis múltiple. No 
obstant, l’evidència actual encara necessita ser reforçada per més estudis que permetin 
acabar de definir els mecanismes pels quals es dona aquesta relació i confirmar 
l’impacte d’aquest tipus de metabòlits a diferents nivells de l’organisme. A la vegada, 
també permetrà generar nous tractaments per a persones que presentin certes 
malalties neurològiques.  
Paraules clau: microbiota, eix microbiota – intestí – cervell, prebiòtics, àcids grassos de 
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This final degree project consists in conducting bibliographic research on current 
scientific evidence about the relationship between short – chain fatty acids (SCFAs) and 
the microbiota – gut – brain axis. 
The project below includes the definition of SCFAs and the microbiota – gut – brain 
axis. There are also described different mechanisms that relate both concepts and 
scientific evidence about their role in certain neurological disorders. 
This is an area that is increasingly being studied due to its impact on human 
pathophysiology. Recent studies show how the gut microbiota influences the 
functioning of the central nervous system (CNS). Through the production of hormones, 
immune factors and metabolites it influences both brain behavior and cognitive 
development. This fact paves the way for a possible therapeutic route (1). 
In addition, the microbiota – gut – brain axis is gaining importance in the investigation 
of psychiatric, neurodevelopmental, neurodegenerative and age - related disorders (2). 
The microbiota has also been shown to play a key role in the regulation of energy 
homeostasis and obesity. Different studies show the relationship between dysbiosis and 
obesity and the role of the microbiota in eating behavior (3). 
Starting from this point, it must be considered that there are several factors that can 
affect the composition of the microbiota such as the type of birth, breastfeeding, 
antibiotic intake, type of feeding, the presence of stressful elements, among others (2). 
The SCFAs are one of the major metabolites of the intestinal microbiota and perform 
various functions in humans (4). These functions and some of their mechanisms are 
described below. 
In order to understand the mechanisms surrounding the effects of SCFAs on this axis, it 
is necessary to continue conducting further studies, and thus develop microbiota – 
based intervention strategies (2). 
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2. OBJECTIVES  
The main objective of this report is to conduct bibliographic research about the 
evidence on the involvement of SCFAs, produced by the gut microbiota, in the 
microbiota – gut – brain axis, a topic with many papers published in the last few 
years. This study will be based on the understanding of different items: 
- Definition of the dietary fiber and prebiotics concepts. 
- Study of the synthesis of short – chain fatty acids by gut microbiota from 
dietary fiber consumption. 
- Study of the functioning of the microbiota – gut – brain axis. 
- Analysis of the impact of short – chain fatty acids on the microbiota – gut – 
brain axis. 
- Research on the role of short – chain fatty acids in different neurological 
disorders. 
3. MATERIALS AND METHODS 
This final degree project is based on an exhaustive bibliographic research. As this is a 
very current topic, the work of nutritional intervention in humans is not very extensive, 
so a fairly inclusive search has been carried out in order to comprise as much information 
as possible and then focus on what is really useful. The main databases used were 
Pubmed and Scopus, where the "5 years" and "review" filters were applied, as well as 
Google Scholar to expand the information. 
First, a general search was made with the terms: “microbiota AND (gut – brain axis)”, 
“microbiota AND brain” and “fiber AND microbiota AND brain”. From all the papers 
published, a selection of the most relevant was performed and analyzed. 
From then on, a more specific search was made using terms such as “fiber AND 
microbiota AND metabolism ” and “microbiota AND brain AND (short chain fatty acids)”. 
It should be noted that many of the articles used were taken from the category "Similar 




4.1. The dietary fiber and prebiotics 
To date, there is still no definition of dietary fiber that is unified by different organisms. 
Historically, dietary fiber was considered to be those polysaccharides with a degree of 
polymerization greater than 10 that are resistant to both digestion and absorption in the 
gut (5). In some recent studies, those substrates with a degree of polymerization 
between 3 - 9 units have been considered as they seem to have the same physiological 
activities as polysaccharides with a degree greater than 10 (6).  
The Regulation (UE) 1169/2011 of the European Union about the provision of food 
information to consumers has defined fiber as «carbohydrate polymers with three or 
more monomeric units, which are neither digested nor absorbed in the human small 
intestine and belong to the following categories: 
- edible carbohydrate polymers naturally occurring in the food as consumed, 
- edible carbohydrate polymers which have been obtained from food raw material 
by physical, enzymatic or chemical means and which have a beneficial 
physiological effect demonstrated by generally accepted scientific evidence, 
- edible synthetic carbohydrate polymers which have a beneficial physiological 
effect demonstrated by generally accepted scientific evidence» (7). 
On the other hand, the current definition of prebiotic was developed by “The 
International Scientific Association for Probiotics and Prebiotics” in 2016. Prebiotic is 
defined as: «Substrate that is used selectively by host microorganisms conferring a 
benefit for the health». With this definition it is clear that in order to be considered 
prebiotic it is necessary to demonstrate that there is a health benefit. Moreover, this 
health benefit must be given through the selective use of the substrate by host 
microorganisms. In addition, it also expands the concept that the substrate may not 





Figure 1. Distinction of what is considered a prebiotic from Gibson GR. et al. (8) 
Unifying both concepts, some types of dietary fiber are candidates to act as prebiotics 
as they are used selectively by the microbiota and produce a beneficial effect. However, 
it can be difficult to categorize dietary fiber as a prebiotic because it also depends on 
some factors such as the host and whether there is a microbiota at the target site 
capable of using it selectively (8). It can be concluded, therefore, that although many of 
the prebiotics belong to the dietary fiber category, not all dietary fiber can be considered 
prebiotic (9).  
4.2. Dietary fiber metabolism to short – chain fatty acids 
The physicochemical characteristics of the fiber are fermentability, solubility and 
viscosity. The types of fermentable fiber include β-glucans, pectins, inulin, 
fructooligosaccharides , resistant maltodextrins, resistant starch, among others (9). 
Dietary fiber plays an important role in the composition, diversity and metabolism of the 
microbiota that produce different metabolites which provide various beneficial 
physiological effects (10). This is a turning point that defines the modulation of the 
microbiota from the food pattern due to the substrate it has available and how it will 
influence its growth and the metabolites produced (9). 
Substrates that have not been able to be digested by human enzymes are candidates to 
be metabolized by the microbiota. It must be considered that there is a difference 
between the microbiota metabolic capacity according to his type of glucosidases. The 
main metabolites resulting from bacterial fermentation are SCFAs and H2 and CO2 
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gases  (9). The SCFAs generated are mainly acetate, propionate and butyrate. These are 
mostly generated in the colon, but the concentration of SCFAs changes along the 
gastrointestinal (GI) tract, being greater in the proximal colon and decreasing in the 
distal colon  (9,10). This decrease may be due to an increase in absorption by SLC5A81 
and SLC16A12 (11).   
When the amount of dietary fiber that arrives is deficient, bacteria move on to 
metabolizing other substrates such as dietary or endogenous proteins and dietary 
fats. These are energetically less favorable substrates for growth and, in addition, cause 
a decrease in the production of SCFAs (11). 
4.2.1. Synthesis, absorption and distribution of short – chain fatty acids 
Dietary fiber is fermented by a variety of gut microbiota specific enzymes leading to 
SCFAs as the main products. Each SCFA has its own synthesis pathway: 
- Acetate: can be produced from pyruvate by the acetyl – CoA pathway and also 
by the Wood – Ljungdahl pathway (11).       
- Butyrate: is synthesized from two molecules of acetyl – CoA and the consequent 
reduction to butyryl – CoA. Butyrate is obtained from the butyryl – CoA molecule 
through the classical pathway. However, it has been shown that some bacteria 
are also able to obtain butyrate from acetate and lactate (11,12).         
- Propionate: its synthesis can be carried out through three pathways. From 
phosphoenolpyruvate there is the acrylate pathway where lactate is reduced to 
propionate and the succinate pathway where it is produced from succinate. The 
third pathway is the propylene glycol one where the synthesis is carried out from 
sugars of deoxyhexose type (11). 
It is estimated that approximately 90–99% of SCFAs are absorbed or used by the 
microbiota (9). SCFAs can diffuse through the intestinal epithelium in a non-ionized 
 
1 SLC5A8: Sodium – coupled monocarboxylate transporter 1 
2 SLC16A1: Monocarboxylate transporter 1 (MCT1) 
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form or through certain transporters such as: SLC16A1, SLC16A3 3 , SLC5A8 and, 
specifically butyrate, SLC22A94 (2). 
But only a small part is detected in blood circulation, mainly acetate and propionate, 
unlike the butyrate which is used locally as a colonocytes energy source (9). Some 
studies have shown that there is a preference in the SCFAs metabolism: butyrate > 
propionate > acetate. The remaining butyrate and most of the propionate are 
metabolized in the liver. The acetate, apart from being the SCFA which is found in higher 
concentrations in peripheral blood, it has also been shown to be able to cross the blood 
– brain barrier (BBB) as certain levels have been detected in the cerebrospinal fluid 
(2,9,11). 
Within the cell, SCFAs can be used as an energy source as they are metabolized primarily 
by the Krebs cycle. As a result, the activity of mTOR, which acts as a sensor of the cellular 
energy levels and is involved in brain physiology and behavior, is increased (2). 
It has been shown that the microbiota belonging to the Bacteroidetes phylum produces 
mainly acetate and propionate unlike the Firmicutes phylum which mainly produces 
butyrate (13). 
4.3. The gut microbiota  
The microbiota is the whole set of microorganisms which are found in different parts of 
the organism where a symbiotic relationship takes place. Of the whole microbiota, the 
one located in the GI tract has the greatest involvement in health due to the different 
functions it performs, some of them vital (4,14). The microbiome is estimated to be 100 
times larger than the human genome (15). 
Among all the microorganisms that inhabit the GI tract, bacteria stand out as the 
majority group. In adulthood it is mainly composed by the Firmicutes and Bacteroidetes 
phylum, with less from the Actinobacteria, Proteobacteria, Fusobacteria, 
Verrucomicrobia and Cyanobacteria phylum (15).  
 
3 SLC16A3: Monocarboxylate transporter 4 (MCT 4) 














Figure 2. Schematic representation of the gut microbiota from Ghaisas S. et al. (4) 
Its composition is not static as it changes throughout life due to factors such as age, diet, 
lifestyle, antibiotics intake, and so on. During the first years of life, the microbiota is 
conditioned by the type of birth and the food the baby receives, whether it is 
breastfeeding or formulas (14). In regard to the diet, changes in the food pattern have 
been seen to cause changes in the microbiota rapidly, even changes are observed 24 
hours after changing a plant – based diet to a diet based on the consumption of animal 
– derived foods and vice versa (13). 
The current evidence shows the great involvement of the microbiota in having a good 
state of health as it is associated with multiple effects that lead to the maintenance of 
homeostasis. Moreover, this can play a key role in certain pathologies (4,15–17). 
It has been seen that the microbiota can play a key role in regulating metabolism and 
appetite control through CNS, so it has the ability to affect the eating behavior in some 
eating disorders and metabolic disorders, such as obesity and malnutrition (15).  
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4.4. The microbiota – gut – brain axis 
The gut – brain axis consists in the bidirectional connection between the GI tract and the 
CNS that is given by afferent neurons of the spinal cord and the vagus nerve (VN) thanks 
to some peptides (neuropeptide Y, cholecystokinin, ghrelin and leptin) and 
neurotransmitters (NT) (dopamine, serotonin, GABA, acetylcholine and glutamate) (4). 
It is a physiological system that integrates the endocrine, immune, GI system, different 
neural pathways, and the brain (13). 
In the recent years, due to the evidence about the microbiota impact on the axis and 
the CNS, the microbiota has been incorporated into this concept, leading to what is 
called the microbiota – gut – brain axis. It has also been studied as potential diagnostic 
and therapeutic tool on various diseases such as Parkinson, Alzheimer, amyotrophic 
lateral sclerosis, autism spectrum disorder (ASD), depressive disorder, and so on (4,17–
21). Alterations in this axis can lead to immunological, neurological, and psychiatric 
illness (13). 
4.4.1. Enteroendocrine cells 
Related to the microbiota – gut – brain axis concept and in order to understand the 
functioning of the different communication pathways and, later, the effects of the SCFAs 
on the axis, it is important to talk about enteroendocrine cells (EEC). These, although 
they represent only 1% of the epithelial cells of the GI tract, play a very important role. 
10 types of EEC have been described and all of them act as a luminal content sensor 
leading to different responses through the production of certain signaling molecules and 
hormones (2,13). 
Two types of cells can be highlighted: enteroendocrine L cells and enterochromaffin 
cells. L enteroendocrine cells, located mostly in the distal small intestine and colon, have 
an apical brush border which is in contact with the intestinal lumen. As for the 
basolateral membrane, it is in contact with the vascular and lymphatic pathways 
allowing secreted hormones to get into circulation rapidly (2,22). 
These cells are able to secrete the "Glucagon-like peptide 1" (GLP-1) and the peptide YY 
(PYY), which have an anorexigenic effect as they are involved in the regulation of 
appetite. Among other substrates, these can be activated by SCFAs through the free 
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fatty acid receptor (FFAR) 2 and FFAR3 receptors that stimulate GLP-1 and PYY secretion 
(2,22). 
In regard to enterochromaffin cells, they are the main producers of serotonin from the 
tryptophan ingested. However, there is less information about its relationship with the 
microbiota (2). 
4.5. Communication mechanisms: 
The communication between the intestinal microbiota and the CNS is carried out 
through several systems such as the autonomic nervous system (NS), enteric nervous 
system (ENS), immune system (IS) and some microbiota metabolites. Bacteria are able 
to activate the secretion of local NT, peptides, hormones and IS mediators. There are 
three different pathways through which information is transmitted: neuronal, 
circulatory and immune pathway (13,23).  
4.5.1. The neural pathway 
The gut is innervated by the sympathetic and parasympathetic NS where the afferent 
fibers transmit information from the gut to the brain unlike the efferent ones that 
project the information to the smooth muscle of the intestine (13). The signals can be 
transmitted to the CNS by afferent nerves originated in the nodular and dorsal root 
ganglia through the VN and the spinal sensory nerves respectively (23). 
The VN belongs to the parasympathetic NS and is the main one involved in the 
communication. This one ends on the intestinal mucosa and transmits information from 
the intestine to the brainstem, so it is a key element of the effects that the microbiota 
has on neurophysiological function (13,24). Besides, it is able to maintain homeostasis 
between the gut and the brain because, among other functions, regulates the secretion 
of NT in the GI system against various pathophysiological conditions (24). 
Although it is known that the VN plays an important role in the microbiota – gut – brain 
axis, is not entirely clear whether the microbiota or its metabolites are those who can 
activate it directly. Since the nerve fibers under physiological conditions have no contact 
with the lumen content, direct activation would occur as a result of an alteration in 
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intestinal permeability. Hence, because the microbiota remains in the intestinal lumen, 
the communication with the afferent pathway is through indirect mechanisms (23).  
The microbiota is capable of producing certain metabolites such as SCFAs, secondary 
bile acids, lipopolysaccharide (LPS), among others that are neuronal modulators (23). 
The GI barrier is made up of a layer of epithelial cells and avoid the lumen content to 
pass through the tissue. The microbiota can secrete some products that stimulate the 
EEC of the intestinal epithelium through certain receptors that are expressed on its 
surface. These cells act as sensors for the lumen content and subsequently send signals 
through the afferent nerves producing different neurohormones such as 
cholecystokinin, GLP-1, PYY and serotonin. That allows, among other functions, to 
regulate the intake, digestion and absorption of nutrients. In addition, metabolites 
produced by the microbiota act as a signal of the enterochromaffin cells and regulate 
serotonin synthesis that activates the VN pathway (23,24). 
It is also necessary to emphasize the existence of the ENS. The ENS and CNS are in 
constant communication via neural pathways. The communication between the 
microbiota and the ENS is performed by metabolites such as SCFAs which are able to 
cross the epithelium to act directly on the ENS. Once they reach the lamina propria, are 
capable of interacting with certain receptors as Toll-like receptors (TLR) and G protein – 
coupled receptor (GPCR) (25). 
4.5.2. The circulatory pathway  
Another way through which the microbiota and the CNS are in contact, is the circulatory 
pathway through intestinal hormones, NT, inflammatory and immunological signals, and 
so on (23). The EEC of the gut are able to secrete certain peptides that communicate 
with the CNS through the afferent nerves in the intestine (neuronal pathway) or they 
reach the brain through bloodstream. It should be noted that through circulation not 
only the flow of microbial metabolites is regulated but also the information that reaches 
the brain from the intestinal microbiota (13). 
Unlike other metabolites such as amino acids, sugars and vitamins that are absorbed by 
active mechanisms through specific transporters, microbiota metabolites can be 
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absorbed by both active and passive mechanisms. In regard to SCFAs, they can be 
absorbed by monocarboxylate transporters or via diffusion. However, in case of a leaky 
gut, a third mechanism is added: the paracellular via (between cells) which can lead to 
an alteration in the microbiota composition and an inflammatory response (13). 
Neurohormones such as serotonin, catecholamines, dopamine… are released to 
circulation by neuroendocrine cells from the intestine. Among these, one of the most 
studied is serotonin, which has been proved to be produced in 90% in the intestine 
under microbiota regulation. However, the peripheral serotonin is not able to cross the 
BBB. In contrast, SCFAs produced by the microbiota once in the bloodstream are able to 
cross the BBB and reach the hypothalamus where they develop different effects (14). 
Compounds capable of crossing the BBB are those with a low molecular weight, little or 
no charge, and have lipid-soluble properties. Therefore, those microbial metabolites 
that meet these physicochemical properties are likely to be able to diffuse into the BBB 
and, as a consequence, develop their effects on the brain (24). 
In addition, it has also been shown that SCFAs that are in the bloodstream can increase 
the production of tight junction proteins called claudin-5 and occludin increasing the 
BBB integrity that limits the access of undesirable metabolites and, at the same time, 







Figure 3. Effect of the SCFAs on BBB permeability from Ma Q. et al. (24) 
4.5.3. The immune pathway  
As a result of the constant communication between the NS and the IS, the effects that 
the microbiota has on the NS cannot be dissociated from those it has on the IS (26). 
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The microbiota is usually found in areas where there is a greater presence of IS elements 
such as immune cells, mucus, immunoglobulin A and some antimicrobial peptides. All of 
them have an important function in order to maintain a homeostatic relationship 
between the microbiota and the organism as they prevent microbial translocation. 
However, the IS also plays an important role in axis communication (13). 
The microbiota is able to secrete some molecules such as LPS which are able to get to 
blood circulation and act as a promoter of innate IS. As a result, inflammatory cytokines, 
which are able to cross the BBB, are secreted. However, it has been seen that the 
microbiota is able to promote the secretion of non-inflammatory cytokines with a 
protective role on the CNS (13,14).  
Some animal studies have suggested that an absence of microbiota may result in a lower 
IS response, so it could be concluded that the presence of microbiota is essential for the 
proper functioning of the IS (13).  
4.6. Short – chain fatty acids  
SCFAs are possibly the most studied microbiota metabolites. Acetate, propionate and 
butyrate make up 95% of the total. These are involved in the regulation of host – 
homeostasis such as GI function, blood pressure regulation, circadian cycle, 
neuroimmune function, brain function and behavior, among others. Different studies 
have shown the great involvement of these compounds in the axis communication 
(2,26,27). 
Although the main source is the microbial fermentation of dietary fiber, there are also 
endogenous sources such as protein catabolism by the microbiota and the metabolism 
of long – chain fatty acids and the conversion of pyruvate to acetate by the host. Also, 
small amounts can be obtained from the consumption of fermented foods (2).  
4.6.1. SCFAs receptors 
In 2003, two receptors, orphans until then, were identified, whose ligands were the 
SCFAs. Both belong to the family of GPCRs, which includes many transmembrane 
proteins where various extracellular molecules can bind. This leads to a large number of 
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physiological effects that include the regulation of the IS, autonomic NS, sensory 
function (taste and smell) and the maintenance of energy homeostasis (12). 
These two receptors are GPR41 and GPR43, which were later named FFAR3 and FFAR2 
respectively. It should be noted that both show a preference for certain ligands 
depending on his chain length. FFAR2 is more specific for acetate and propionate, unlike 
FFAR3 which has a higher affinity for butyrate (12). However, some other studies also 
point to propionate as a FFAR3 ligand (28). 
Some studies also include the GPR109A receptor as a target only for butyrate 
(2,12,25,29). 
Related to the location, each receptor is located on the membranes of certain cell types 
throughout the body. However, although there are some differences between studies, 
they do agree on the fact that the three receptors are located in the colon, among other 
cells (2,29,30).  
Receptor  Location Bibliography 
FFAR2 
Colon, immune cells, heart, 
adipose tissue (AT) and skeletal 
muscle 
(2) Cryan JF, O’riordan KJ, Cowan CSM, 
Sandhu K V., Bastiaanssen TFS, Boehme 
M, et al. The microbiota-gut-brain axis. 
Physiol Rev. 2019;99(4):1877-2013.  
Intestinal leukocytes, 
enteroendocrine cells, intestinal 
epithelium and white AT. 
(29) Sivaprakasam S, Prasad PD, Singh N. 
Benefits of short-chain fatty acids and 
their receptors in inflammation and 
carcinogenesis. Pharmacol Ther. 
2016;164:144-51. 
Immune cells (neutrophils, 
eosinophils, lymphocytes, 
monocytes), pancreas (β cells), 
intestinal cells (enteroendocrine L 
cells and epithelial cells) and white 
AT. 
(30) Grundmann M, Bender E, 
Schamberger J, Eitner F. Pharmacology 
of free fatty acid receptors and their 





Colon, immune cells, heart, 
peripheral NS and BBB 
 
(2) Cryan JF, O’riordan KJ, Cowan CSM, 
Sandhu K V., Bastiaanssen TFS, Boehme 
M, et al. The microbiota-gut-brain axis. 
Physiol Rev. 2019;99(4):1877-2013. 
Enteric neurons, enteroendocrine 
cells and pancreas 
(29) Sivaprakasam S, Prasad PD, Singh N. 
Benefits of short-chain fatty acids and 
their receptors in inflammation and 
carcinogenesis. Pharmacol Ther. 
2016;164:144-51. 
Peripheral NS, pancreas (β cells), 
intestinal cells (L enteroendocrine 
cells, K cells) and immune tissue 
(dendritic cells and thymus) 
(30) Grundmann M, Bender E, 
Schamberger J, Eitner F. Pharmacology 
of free fatty acid receptors and their 
allosteric modulators. Int J Mol Sci. 
2021;22(4):1-38.  
 
Table 1. Location of FFAR2 and FFAR3 receptors throughout the body. 
4.6.2. Effect of the short – chain fatty acids on the microbiota – gut – brain axis 
SCFAs are GPCR ligands leading to many effects such as the promotion of energy and 
glucose homeostasis due to their use as an energy source, the regulation of the immune 
and inflammatory system responses, also hormones that control the feeling of satiety 
and finally the regulation of the central and peripheral NS (16).  
By means of the FFAR2, receptor they have a protective and homeostatic effect on the 
colon as they are able to regulate the colonic regulatory T cell (Treg). As for the FFAR3 
receptor, it has been shown to has the ability to promote beneficial metabolic effects 
including the control of body weight and glucose through the gut – brain axis (25).  
➔ GLP-1 and PYY peptides regulation 
The main stimulus for GLP-1 and PYY secretion is food intake and digestion as an increase 




Since SCFAs are ligands of the endogenous FFAR2 and FFAR3 receptors of 
enteroendocrine L cells, they are involved in the control of the secretion into the 
bloodstream of anorexigenic intestinal peptides such as GLP-1 and PYY  (3,13,15,28).  
GLP-1 and PYY are involved in the regulation of appetite through both central and 
peripheral pathways as they decrease the intestinal motility, regulate glucose 
homeostasis and energy expenditure and, in addition, decrease appetite and food intake 
(32). It should be noted that the effect of decreasing appetite and food intake by GLP-1 
is through the autonomic NS and the brain (28). 
In subjects supplemented with prebiotics, an increase in plasma of both peptides and 
also the feeling of satiety could be observed. This could contribute to a change in 
appetite and, therefore, its use as a treatment for obesity is being considered (16). 
Also, it has been seen that the SCFAs regulate the production of PYY from EEC by 
inhibiting the histone deacetylase (2,22). However, this effect is specific to certain 
species such as humans, but not in mouse cells and, therefore, in this case, mouse is not 
valid as a study model (22). 
Emphasis should be made on the importance of the colon area where the SCFAs act, 
since it has been seen that the infusion of acetate in the distal colon produce an increase 
in circulating PYY levels unlike when it is made in the proximal colon (2). 
One study showed that acetate plays a role in the central control of appetite by 
regulating regions such as the hypothalamus. This effect occurs through activation of 
acetyl-CoA carboxylase which leads to changes in the expression of GLP-1 and PYY. 
However, it should be noted that this study was performed on a mouse model (13). 
Also, there has been seen an increase of GLP-1 and PYY in the plasma due to an increase 
in the propionate levels. In addition, an increase in propionate production has been seen 
to lead to lower subjective appeal by individuals to high calorie foods and also low 
energy intake during an ad libitum5 meal (13). 
 
 
5 ad libitum: without restrictions.  
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➔ Effect on hormones: insulin, glucagon, leptin and ghrelin. 
Another effect of the SCFAs is its impact on other hormones such as insulin, glucagon, 
leptin and ghrelin (15). However, many more studies are still needed, especially in 
humans, in order to obtain stronger evidence. 
- Insulin and glucagon 
The GLP-1 increases insulin secretion from the beta – pancreatic cell and decreases 
glucagon secretion. This effect leads to a lower blood glucose levels as it results in lower 
liver glucose production and an increased uptake by tissues (28).  
In a study done on overweight adults was administered 10 grams of inulin – propionate 
ester for 24 weeks. The results directed to a reduction of weight gain, intra – abdominal 
AT distribution and intra – hepatocellular lipid content and also improved insulin 
resistance compared to the control group who only consumed inulin (17,33). 
- Leptin 
Leptin is a peptide secreted by adipocytes and to a minor degree from gastric parietal 
cells. This has several functions such as to decrease appetite, weight gain and adiposity. 
Its receptors are found in different areas of the brain which are involved in controlling 
appetite and also in the afferent nerves of the VN  (34). Leptin provides the brain with 
information about energy storage. By inhibiting orexigenic AgRP neurons and activation 
of anorexigenic POMC neurons, leptin is able to decrease the intake and increase energy 
expenditure (35). 
Some studies mention that leptin is secreted due to the binding of SCFAs to the FFAR3 
receptor which is in adipocytes resulting in a decreased appetite. Therefore, this effect 
goes alongside GLP-1 and PYY (28). 
In some in vitro studies, it has been shown that activation of FFAR3 by SCFAs on the AT 
resulted in an increased leptin expression (15,35). In the same way, oral propionate 
administration has been shown to increase circulating leptin levels. It should be noted, 
that these studies are done in rodents (35,36). 
23 
 
Another study showed an increased leptin expression after administering an ex vivo 
treatment on human AT with propionic acid6. Specifically, showed that the 1 and 3 mM 
doses increased their expression by 65 and 100% respectively. On the contrary, the 10 
mM concentration resulted in no significant changes (37,38). 
In a study done on rodents it was seen that both acetate and propionate7 resulted in an 
increase in leptin gene transcription. However, more in vivo studies are required in order 
to study this relationship (39). 
It should be noted that some of these studies refer to the FFAR3 receptor when the 
articles detailing the location of these receptors do not indicate that this receptor is 
located in AT. However, it cannot be ruled out and more studies should be done. 
- Ghrelin 
The ghrelin is secreted primarily in the stomach. This one is involved in regulating the 
intake, body weight, adiposity, insulin secretion, glucose metabolism, stomach acid 
secretion and stimulation of intestinal motility (34).  
Among other receptors, ghrelin – secreting cells have on their surface the FFAR2 
receptor which has SCFAs as a ligand. Their binding results in an inhibition of ghrelin 
secretion (31).  
Ghrelin response differs from the other gut hormones since it shows an opposite 
fluctuation in plasma (32). Higher levels are obtained between meals and decrease post-
intake (31). In addition, compared to the others hormones, ghrelin has opposite effects: 
stimulation of gastric emptying, hunger, glucagon secretion and inhibition of insulin 
secretion and thermogenesis (32). 
 
6 Concentrations of 0, 0.01, 0.1, 1, 3 and 10 mM (38)  










Figure 4. Scheme about the opposite endocrine and metabolic effects of ghrelin and GLP-1 from 
Engelstoft MS. et al. (31) 
In addition, ghrelin crosses the BBB where is able to activate AgRP neurons and inhibit 
POMC neurons leading to an overall appetite – boosting effect (37). 
In regard to the control of ghrelin and GLP-1 secretion, GPCR ligands cause an inhibitory 
and stimulatory effect respectively. This fact offers the research for possible strategies 
in order to obtain both effects through the same mechanism (31). 
➔ Effects on serotonin 
Serotonin has several functions such as regulating satiety, anxiety, mood, stimulation of 
peristalsis, secretion and vasodilation. In addition, there is also some evidence of its role 
in relation to lipid and glucose metabolism (37). 
On the hypothalamus, it is able to regulate food intake decreasing it by inhibiting AgRP 
neurons and activating POMCs (37). 
In regard to the SCFAs, it has been seen that are able to increase the synthesis and 
secretion of serotonin (15,18). However, it should be noted that it is not able to cross 
the BBB (37). 
More than 90% of the serotonin we produce comes from the enterochromaffin cells of 
the intestine where it regulates peristalsis, among other functions. From EEC human 
treated with acetate and butyrate, it was observed that there was a concentration – 
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dependent increase in mRNA expression of the Tph1 gene.  Tph1 is a limiting enzyme in 
the serotonin synthesis. Then, is stored in granules before being released (35,40).  
In addition, serotonin participates in fasting – induced adaptation as it is able to promote 
lipolysis in AT and gluconeogenesis in liver. Thus, energy availability increases (35). 
Also, propionate has been shown to be able to modulate serotonin secretion in the gut 
and decrease its levels in the brain. This can lead to an excess of serotonin in plasma 
that has been observed in children with ASD (41). 
Peptides/ 
Hormones / NT 
SCFAs effect Main physiological effects 
GLP-1 ↑ - ↓ Intestinal motility 
- Glucose homeostasis and energy 
expenditure regulation  
- ↓ Appetite and food intake 
PYY ↑ 
Insulin ↑ (Indirect effect) - ↓ Glycemia 
- Improving of insulin resistance Glucagon ↓ (Indirect effect) 
Leptin ↑ - ↓ Appetite and food intake 
- ↓ Weight gain and adiposity 
- ↑ Energy expenditure  
Ghrelin ↓ - ↓ Appetite 
- Body weight, adiposity and glucose 
metabolism regulation 
- ↓ Stomach acid secretion, gastric 
emptying and intestinal motility  
- ↓ Glucagon secretion  
- ↑ Insulin secretion 
- ↑ Thermogenesis  
Serotonin ↑ - ↑ Lipolysis in AT and gluconeogenesis 
in liver  → ↑ energy availability  
- Regulation of satiety, anxiety, mood, 
stimulation of peristalsis, secretion and 
vasodilation 
 
Table 2. Main effects of the SCFAs on peptides (GLP-1 and PYY), hormones (insulin, glucagon, leptin and 
ghrelin) and NT (serotonin) and their resulting physiological effect 
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➔ Effects on the nervous system 
Finally, one of the effects that SCFAs develop on the body is on the NS. 
Butyrate has been shown to be able to increase the proportion of cholinergic neurons 
by epigenetic mechanisms. Therefore, the effects on NS by SCFAs are not limited to 
neuronal activation (15).  
The FFAR3 receptor is also expressed in the ENS. When SCFAs cross the intestinal 
epithelium and reach the portal vein, signaling through the FFAR3 receptors of the portal 
nerves by propionate takes place. This fact leads to an increase in the activity of the 
dorsal vagal complex that receives signals from the VN and the hypothalamus, which 
participates in the control of appetite and metabolism (3,15).  
In addition, through FFAR3 receptors located in sympathetic ganglionic neurons, SCFAs 
can directly activate the sympathetic NS (42).  
Also, SCFAs can cross the BBB and help maintain their integrity. SCFAs influence 
neuronal signaling and NT production as they increase the expression of anorexigenic 
peptides in the hypothalamus and regulate the levels of GABA, glutamate and 
glutamine. Thus, they may have an impact on behavior (14,42).  
Figure 5. SCFAs involvement in the regulation of appetite and metabolism from van de Wouw M. et al. (15). 
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4.7. Involvement of SCFAs in some neurological disorders 
There is an increasing evidence about the relationship between microbiota and different 
neurological disorders such as ASD, Parkinson, Alzheimer, and so on (4,17–21). 
However, the evidence of the SCFAs in relation to these disorders is not so clear. 
Some compounds produced by the microbiota such as LPS, bacterial lipoproteins, 
flagellin, and CpG islands of unmethylated DNA are capable of stimulate cytokine 
secretion by IS innate cells. These cytokines are able to cross the BBB and activate 
microglia and certain neurons resulting in altered neuronal function that can affect 
mood and behavior. Based on this fact, it is important to have in mind the role that SCFAs 
play in the integrity of BBB through the production of the tight junction proteins that 
limit the access of certain molecules through it (16). 
GPCRs are also found in the CNS where they are involved in the regulation of 
metabolism, inflammation, neurological disorders and other diseases (25). SCFAs can 
cross the BBB and participate in neuronal signaling, NT production, and behavior (42).  
Moreover, SCFAs are able to induce the Treg proliferation by histone modifications, 
increasing acetylation and decreasing deacetylation at Foxp3+ promoter region (24,43). 
Also, they have been shown to stimulate the production of retinoic acid in the intestine, 
which inhibits Th17 cell differentiation and promotes the proliferation of Treg leading 
to beneficial effects on neuroinflammation (12,24,30). Therefore, all these actions go in 
the direction of controlling inflammation and improving the IS functioning. 
Another important concept to consider is the intestinal permeability. Some products of 
the microbiota have been shown to be involved in the maintenance of the intestinal 
barrier. For example, SCFAs have been shown to act as trophic factors of the mucosa 
and epithelial layer (3,42). Moreover, butyrate has effects on mucin production, anti – 
inflammatory effects, and increase tight junction proteins leading to a better 
maintenance of the intestinal barrier and reduced permeability (44). 
Increased permeability can lead to translocation of the microbiota or its products such 
as LPS so, IS is activated and pro – inflammatory cytokines are secreted. These, as 




Figure 6. Interaction between microbiota, intestinal permeability and CNS from Yarandi SS. et al. (42) 
➔ Parkinson’s disease  
The Parkinson's disease is a neurodegenerative disorder quite common among the 
population. The main feature that accompanies this disorder is the loss of dopaminergic 
neurons in substantia nigra and the accumulation of α – synuclein and Lewis bodies. 
Recent evidence suggests that accumulation of α – synuclein starts in ENS where it is 
associated to some digestive symptoms (2,24). Due to the implication of SCFAs in the 
regulation of IS, certain strategies can be contemplated as an effective treatment of the 
disease (24). 
In these patients, a lower amount of Prevotellaceae has been found which is a genus 
producer of SCFAs (43). In fact, decreased levels of SCFAs have been found in the feces 
of Parkinson’s patients compared with controls (19,43). 
➔ Autism spectrum disorder  
As for ASD, it is a neurodevelopmental disorder that has an important genetic basis (13).  
Given the neuroactive properties of SCFAs we should not stop studying the relationship 
with this disorder (2).  
It is also important to note that in children with ASD a higher intestinal permeability has 
been observed which leads to an increase in LPS. This leads to an inflammatory state as 
a result of the secretion of pro – inflammatory  cytokines such as IL-6 (42). 
Several preclinical studies in rodents have shown how neurotoxic doses8 of propionic 
acid induce a similar behavior in ASD (2,45,46).  
 
8 Intracerebroventricular administration of 4 μl of a solution that contains 0.26 M of propionic acid (45,46) 
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Also, some studies show the relationship between certain levels of SCFAs and the 
pathogenesis of ASD. In children with this disorder, high levels of acetic acid and 
propionic acid have been found in both feces and serum, as well as increased production 
by the microbiota. However, the exact mechanisms by which SCFAs are involved are not 
known yet (41). 
So, according to these latest studies, it seems that SCFAs play a negative role in this 
disorder. 
On the other hand, some studies have shown that children with ASD have significantly 
higher levels of Clostridium and lower levels of healthy bacteria and metabolites such as 
SCFAs compared to the control group (17). Therefore, because of these contradictory 
studies, the SCFAs role on this disorder is still unclear (13). 
➔ Multiple Sclerosis  
Multiple sclerosis is an inflammatory disease where there is a demyelination of neuronal 
axons. It has been seen an abnormal immune response to the secretion of pro-
inflammatory cytokines due to an increased activity of Th1 and Th17 cells, which can 
lead to infiltration of immune cells in the CNS. In these patients, this fact has been 
accompanied by lower activity of Treg worsening autoimmune reactions (24). Some 
studies have shown the ability of SCFAs to decrease Th17 cells and increase Treg 
proliferation (12,24,30). 
Also, an experimental model of multiple sclerosis showed that the administration of 
propionic acid improved the disease course because a lower inflammatory state of the 
CNS resulted in less neuronal demyelination (43). 
Although there is growing evidence that understanding of the microbiota – gut – brain 
axis could lead to strategies for the prevention and treatment of certain brain disorders, 




5. DISCUSSION  
Current evidence appears to show a relationship between SCFAs and the microbiota – 
gut – brain axis through their effect at different levels. 
Considering diet as one of the factors that regulates the microbiome, and this one, at 
the same time, conditions the production of SCFAs, it is necessary to highlight the role 
of the pattern of eating habits in everything that surrounds the microbiota – gut – brain 
axis. 
Following high – fat and high – sugar diets usually leads to lower fiber intake, which can 
lead to dysbiosis. At the same time, this results in a decreased synthesis of some 
beneficial products by the microbiota such as SCFAs (3). 
Also, the antibiotics and other drugs intake are other factors that can lead to dysbiosis. 
It should be noted that a state of dysbiosis can lead to negative consequences on 
neurological and mental health status (27). 
Although studies are still needed to correctly define the impact of SCFAs on the 
microbiota – gut – brain axis, one of the effects that has been seen more clearly is the 
GLP-1 increase. However, other effects like the one it has on leptin are not so clear and 
more studies are needed. 
The overall effect, consists in a decrease in appetite and food intake, regulation of 
glucose homeostasis, energy expenditure and control of body weight. 
In relation to GLP-1, currently, there are pharmacological therapies that mimic this 
peptide and are indicated in people with diabetes and even one of them exclusively in 
obesity (Saxenda®). Some of these active ingredients are: Dulaglutida (Trulicity®), 
Exenatida (Bydureon®, Byetta®), Semaglutida (Ozempic®, Rybelsus®), Liraglutida 
(Victoza®, Saxenda®) i Lixisenatida (Adlyxin®). Even though, Rybelsus ® and Adlyxin ® are 
not marketed in Spain (47). 
These are drugs that, despite their proven effectiveness, are not first – line treatments 
in type 2 diabetes due to their higher cost and method of administration that, unlike the 




Although SCFAs effect is in the same direction as these drugs by increasing GLP-1, their 
effect is currently not comparable. Among other reasons, because the production of 
SCFAs from dietary fiber is highly variable depending on the person. Consumption of the 
same type and amount of fiber by different subjects does not imply that it results in the 
production of the same amount of SCFAs. That is because it depends, among other 
things, on the type of microbiota the subject has. However, if the possibility of 
consuming SCFAs directly is contemplated, more studies would be needed to analyze 
the efficacy in relation to increasing GLP-1. 
Another study area is their relationship with some neurological diseases like Parkinson, 
ASD and multiple sclerosis. The involvement of the microbiota in these types of 
disorders is becoming more important. However, more studies are needed to obtain 
clear conclusions about SCFAs role. 
Within this area, should be emphasized the importance of continuing with the study of 
possible strategies for future treatments that may be beneficial for individuals suffering 
from these types of neurological disorders. 
On the other hand, it should be considered that one of the limitations of some of the 
studies is that they are made in animals, mainly rodents. This fact represents an obstacle 
due to the rodent’s diet differs from the human’s diet, which makes the comparison 
between both microbiota problematic (4). 
Most reviews show that more studies are still needed in order to define the SCFAs 
impact on the axis. In relation to this, not all studies have identical results due to the 
methodology used among other factors. However, they also emphasize the importance 
of continuing to study this relationship. 
6. CONCLUSION 
After the research, it can be concluded that the SCFAs produced by the gut microbiota 
have an involvement in microbiota – gut – brain axis. However, it should be emphasized 
that while some of the effects are well – proven, others still require more study. 
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Also, it should be noted that the information collected was different depending on the 
article consulted creating some contradictions. These, once again, leads to the 
conclusion that more studies have to be performed. 
Currently there is a deficient fiber intake in the population. In a study done in an adult 
Spanish population between 18 and 64 years old, the fiber consumption was 12.5 ± 5.66 
g / day on average. This consumption is below from the European Food Safety Authority 
(EFSA) recommendation (25 g / day) (49,50). 
Finally, considering the results of this research that show the potential beneficial effects 
of the SCFAs, could be added one more reason why is important to increase the fiber 
intake. However, as already mentioned, although most prebiotics belong to the fiber 
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